Use of apraclonidine to reduce acute intraocular pressure rise following Q-switched Nd:YAG laser iridotomy.
We evaluated the effectiveness of topical apraclonidine (ALO 2145, p-amino clonidine hydrochloride) in suppressing an acute postoperative intraocular pressure (IOP) rise following Nd:YAG laser iridotomy. Fifty-eight eyes (45 patients) with chronic primary angle-closure glaucoma underwent Q-switched Nd:YAG laser iridotomy. Twenty-nine eyes followed prospectively underwent Nd:YAG laser iridotomy following the topical administration of 0.5% apraclonidine prior to and immediately following the procedure. A retrospective control group of 29 eyes underwent Nd:YAG laser iridotomy without topical apraclonidine. Only one eye (3.4%) treated with apraclonidine experienced an IOP rise greater than 10 mm Hg over baseline, while five among 29 untreated eyes (17.2%) developed an IOP rise greater than 10 mm Hg.
Kitazawa
Y
Y
Department of Ophthalmology, Gifu University School of Medicine, Japan.
Taniguchi
T
T
Sugiyama
K
K
D000368:Aged; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005901:Glaucoma / Q000601:surgery; D006068:Gonioscopy; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D007498:Iris / Q000601:surgery*; D053685:Laser Therapy / Q000009:adverse effects*; D008297:Male; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000209:etiology; D011183:Postoperative Complications; D011446:Prospective Studies; D013997:Time Factors
C016986:apraclonidine; D003000:Clonidine